IL244312B - Administration of kynurenine depleting enzymes for tumor therapy - Google Patents

Administration of kynurenine depleting enzymes for tumor therapy

Info

Publication number
IL244312B
IL244312B IL244312A IL24431216A IL244312B IL 244312 B IL244312 B IL 244312B IL 244312 A IL244312 A IL 244312A IL 24431216 A IL24431216 A IL 24431216A IL 244312 B IL244312 B IL 244312B
Authority
IL
Israel
Prior art keywords
kynurenine
administration
tumor treatment
reducing enzymes
enzymes
Prior art date
Application number
IL244312A
Other languages
English (en)
Hebrew (he)
Other versions
IL244312A0 (en
Inventor
Georgiou George
Stone Everett
Original Assignee
Univ Texas
Georgiou George
Stone Everett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Georgiou George, Stone Everett filed Critical Univ Texas
Publication of IL244312A0 publication Critical patent/IL244312A0/en
Publication of IL244312B publication Critical patent/IL244312B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y307/00—Hydrolases acting on carbon-carbon bonds (3.7)
    • C12Y307/01—Hydrolases acting on carbon-carbon bonds (3.7) in ketonic substances (3.7.1)
    • C12Y307/01003—Kynureninase (3.7.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL244312A 2013-08-30 2016-02-28 Administration of kynurenine depleting enzymes for tumor therapy IL244312B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361872132P 2013-08-30 2013-08-30
US201461986366P 2014-04-30 2014-04-30
PCT/US2014/053437 WO2015031771A2 (en) 2013-08-30 2014-08-29 Administration of kynurenine depleting enzymes for tumor therapy

Publications (2)

Publication Number Publication Date
IL244312A0 IL244312A0 (en) 2016-04-21
IL244312B true IL244312B (en) 2019-03-31

Family

ID=52583559

Family Applications (2)

Application Number Title Priority Date Filing Date
IL244312A IL244312B (en) 2013-08-30 2016-02-28 Administration of kynurenine depleting enzymes for tumor therapy
IL264901A IL264901B (en) 2013-08-30 2019-02-19 Administration of kynurenine depleting enzymes for tumor therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL264901A IL264901B (en) 2013-08-30 2019-02-19 Administration of kynurenine depleting enzymes for tumor therapy

Country Status (12)

Country Link
US (5) US9808486B2 (enExample)
EP (2) EP3038636B1 (enExample)
JP (4) JP6307163B2 (enExample)
KR (2) KR102442231B1 (enExample)
CN (2) CN105722522B (enExample)
AU (1) AU2014312119B2 (enExample)
BR (1) BR112016004095A2 (enExample)
CA (2) CA3173052A1 (enExample)
ES (1) ES2707711T3 (enExample)
IL (2) IL244312B (enExample)
WO (1) WO2015031771A2 (enExample)
ZA (1) ZA201601443B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA3173052A1 (en) 2013-08-30 2015-03-05 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
IL250833B (en) 2014-08-29 2022-09-01 Univ Texas Administration of kynurenine depleting enzymes for tumor therapy
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
WO2016149665A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
WO2017123675A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
EP3423483B1 (en) * 2016-03-02 2025-09-24 Board Of Regents Of the University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
EP3525803B1 (en) 2016-10-13 2022-12-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
AU2018301668A1 (en) * 2017-07-12 2019-12-19 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2019089740A1 (en) * 2017-11-03 2019-05-09 Dana-Farber Cancer Institute, Inc. Biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
CA3096549A1 (en) 2018-04-16 2019-10-24 Board Of Regents, The University Of Texas System Human kynureninase enzymes and uses thereof
CN110412179A (zh) * 2018-04-26 2019-11-05 缪荣明 一种液相色谱检测颗粒酶a的方法
EP3893923A2 (en) * 2018-12-14 2021-10-20 Autolus Limited Cell
CN114828863A (zh) * 2019-10-17 2022-07-29 医肯纳肿瘤学公司 聚乙二醇化犬尿氨酸酶以及其用于治疗癌症的用途
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
WO2023229024A1 (ja) * 2022-05-27 2023-11-30 富士フイルム株式会社 血液腫瘍の診断を補助する方法、血液腫瘍の診断を行うためのデータを得る方法、及びこれらの方法のためのキット
WO2024085280A1 (ko) * 2022-10-20 2024-04-25 서울대학교 산학협력단 신규한 키뉴레니나제 및 이의 용도

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030194721A1 (en) 2001-09-19 2003-10-16 Incyte Genomics, Inc. Genes expressed in treated foam cells
US20030215840A1 (en) 2002-02-01 2003-11-20 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules
CN1330774C (zh) * 2002-03-01 2007-08-08 国家人类基因组南方研究中心 犬尿氨酸水解酶多态性及其用途
WO2004094409A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
JP2008237022A (ja) 2005-06-30 2008-10-09 Osaka Prefecture 非小細胞肺がんの予防・治療剤および診断薬
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
GB0625310D0 (en) * 2006-12-19 2007-01-24 Bioalvo Yeast platform construction and screening methods
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
EP3115373B1 (en) 2010-09-08 2019-08-28 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20120085209A (ko) * 2011-01-21 2012-07-31 인제대학교 산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물
WO2012099441A2 (ko) 2011-01-21 2012-07-26 인제대학교산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물
HK1201471A1 (en) * 2011-09-07 2015-09-04 Deutsches Krebsforschungszentrum Means and methods for treating and/or preventing natural ahr ligand-dependent cancer
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗ｃｄ２２キメラ抗原受容体
CA3173052A1 (en) * 2013-08-30 2015-03-05 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
IL250833B (en) 2014-08-29 2022-09-01 Univ Texas Administration of kynurenine depleting enzymes for tumor therapy
EP3423483B1 (en) 2016-03-02 2025-09-24 Board Of Regents Of the University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
JP6912171B2 (ja) * 2016-09-15 2021-07-28 株式会社トプコン 眼科検査装置
CA3096549A1 (en) 2018-04-16 2019-10-24 Board Of Regents, The University Of Texas System Human kynureninase enzymes and uses thereof

Also Published As

Publication number Publication date
EP3038636B1 (en) 2018-11-07
US20240091258A1 (en) 2024-03-21
KR102271498B1 (ko) 2021-07-05
ES2707711T3 (es) 2019-04-04
US20200054674A1 (en) 2020-02-20
CA2922670C (en) 2022-11-29
EP3038636A2 (en) 2016-07-06
CA2922670A1 (en) 2015-03-05
NZ717492A (en) 2021-10-29
KR102442231B1 (ko) 2022-09-13
KR20160048971A (ko) 2016-05-04
US9808486B2 (en) 2017-11-07
KR20210082264A (ko) 2021-07-02
US12680089B2 (en) 2026-07-14
JP7029316B2 (ja) 2022-03-03
WO2015031771A2 (en) 2015-03-05
CA3173052A1 (en) 2015-03-05
JP2016533753A (ja) 2016-11-04
CN105722522A (zh) 2016-06-29
EP3492094A1 (en) 2019-06-05
JP6307163B2 (ja) 2018-04-04
JP2022159570A (ja) 2022-10-17
US10772913B2 (en) 2020-09-15
AU2014312119A1 (en) 2016-03-17
AU2014312119B2 (en) 2019-09-19
BR112016004095A2 (pt) 2017-10-17
ZA201601443B (en) 2019-08-28
EP3038636A4 (en) 2017-04-26
IL244312A0 (en) 2016-04-21
CN113957061A (zh) 2022-01-21
JP2018127463A (ja) 2018-08-16
WO2015031771A3 (en) 2015-05-14
US20150064154A1 (en) 2015-03-05
CN105722522B (zh) 2021-10-19
US11534463B2 (en) 2022-12-27
US20170056449A1 (en) 2017-03-02
US20210213059A1 (en) 2021-07-15
IL264901B (en) 2019-08-29
JP2020111611A (ja) 2020-07-27

Similar Documents

Publication Publication Date Title
IL264901B (en) Administration of kynurenine depleting enzymes for tumor therapy
IL283943A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
LT2885010T (lt) Tautopatijos gydymo būdai
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
SI3033086T1 (sl) Kombinirana terapija za zdravljenje raka
HUE046790T2 (hu) A rák kezelésének módszerei
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
LT2846809T (lt) Mielosupresijos gydymas
LT3007726T (lt) Tautopatijos gydymo būdai
PT3626270T (pt) Tratamento de doenças cardiovasculares
IL240987A0 (en) Methods for treating solid tumors in children
HUE046728T2 (hu) Rák és jóindulatú proliferációs rendellenességek kezelése
HUE061493T2 (hu) Vetõmagok fertõtlenítõ kezelése
PL2914261T3 (pl) Śmiertelność syntetyczna i leczenie nowotworu
PT3511004T (pt) Preparações combinadas para o tratamento de cancro
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
DK3563837T5 (da) Bakteriofagterapi
IL234606B (en) Novel methods and composition for treatment of disease
HRP20182041T1 (hr) Pripravci oksprenolola za liječenje raka
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
IL242220A0 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
HUE045947T2 (hu) Formuláció IBS kezelésére

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed